CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Sept. 30, 2019—Roche announced the commercial availability of the Cobas EBV (Epstein-Barr virus) and Cobas BKV (BK virus) tests for use on the Cobas 6800/8800 systems in countries accepting the CE mark. The tests are used to assess transplant patients’ risk of developing disease by these pathogens, which can contribute to organ rejection.
“These two new in vitro diagnostic tests provide transplant patients with peace of mind that their doctors have access to best-in-class monitoring tools so that treatment plans can be adjusted as necessary,” Mario Torres, head of Roche Molecular Diagnostics, said in a company press release. “The tests meet World Health Organization standards and will provide critically needed and comparable results across institutions to increase the quality of care.”